fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA approves Voxzogo (vosoritide) for children under 5 years with achondroplasia – BioMarin

Written by | 24 Oct 2023

BioMarin Pharmaceutical Inc. announced that the FDA has approved the supplemental New Drug Application (sNDA) for Voxzogo (vosoritide) to increase linear growth in pediatric patients with achondroplasia with… read more.

BioMarin announces first person treated commercially with Roctavian for severe hemophilia A in Europe

Written by | 2 Sep 2023

BioMarin Pharmaceutical Inc. announced that an individual in Germany with severe hemophilia A was treated with Roctavian (valoctocogene roxaparvovec-rvox), marking the first time that the gene therapy has… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.